Immunogenicity Testing-MAPPs

About ImmuneSpec

Founded in 2017 and based in Leuven, Belgium, ImmuneSpec is a specialized service provider in the immunopeptidomics space. The company leverages a proprietary, high-sensitivity platform to identify peptides presented by MHC molecules, offering crucial insights for biotherapeutic developers in immunogenicity testing, vaccine design, and cancer immunotherapy target validation. As a private, likely pre-revenue or early-revenue company, ImmuneSpec operates on a B2B service model, partnering with pharmaceutical and biotech clients to de-risk and accelerate their R&D pipelines through precise, data-driven epitope mapping.

Therapeutic Areas